Tarsus nabs key data in hunt to repurpose dog drug as cure for eye parasite
Eight months after their $101 million IPO, Tarsus Pharmaceuticals say they’ve cleared the first of two trials needed to prove to their FDA that their repurposed dog drug can successfully banish mites from patients’ eyes.
The California biotech announced Monday that, in a Phase II/III study, 81% of patients with the common eye infestation Demodex blepharitis achieved a “clinically meaningful” cure of infestation-induced lesions after taking the drug, called TP-03. That compared to 23% of patients on placebo. And, on the secondary endpoint, 68% of patients saw their mites eradicated entirely — compared to 18% on placebo.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.